7 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... #Tuberculosis ... #ActiveTB #RIPE ... #medications #pharmacology ... #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Regimen for Multi-Drug ... are contacts of infectious ... #MDRTB #management ... #regimens #pharmacology
IDSA Summary of recommendations on drugs for use in a treatment regimen for patients with
multidrug-resistant tuberculosis,
IDSA Summary of ... recommendations on drugs ... regimen for patients ... #MDRTB #management ... #pharmacology #
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
drug use • Silicosis ... Tuberculin skin test ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
drug use • Silicosis ... Tuberculin skin test ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... RAL-based ART regimen ... #TB #IDSA #Prevention ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Disease: • CMV end-organ ... disease is best ... intraocular levels of drug ... #HIVAIDS #pharmacology